The research centers on the hypothesis that using combinations of compounds to target
multiple viral replication mechanisms may improve treatment outcomes. Specifically,
Taval and Mody are evaluating whether these strategies can reduce drug resistance,
improve antiviral effectiveness, suppress inflammatory cytokine responses, and minimize
toxicity through lower doses of individual agents.
This approach aims to address some of the limitations of monotherapies, such as reduced
efficacy against emerging viral variants and the potential for adverse effects at
higher dosages, Taval explained.
Key Points
Dr. Taval is leading research at PCOM Georgia on developing combination antiviral
therapies using small molecular compounds to treat COVID-19 and future viral threats.
The research explores how targeting multiple viral mechanisms can improve outcomes
and reduce issues like drug resistance and toxicity.
Taval incorporates this research into PharmD coursework, linking scientific advances
with practical instruction in virology and pharmacology.
The research was recently published in Scientific Reports (February 2025), as part of a study that found the compound 9-aminominocycline increases the antiviral
effectiveness of EIDD-1931 and PF-332 by targeting the papain-like protease enzyme
of SARS-CoV-2. These findings support further evaluation of combination therapies
as a possible route toward broad-spectrum antiviral solutions.
“Solving this problem is important because current COVID-19 treatments face challenges
like drug resistance, limited spectrum, and dose-related toxicity,” Taval said.
Taval’s interest in research began with a focus on molecular disease mechanisms and
evolved into an emphasis on targeted therapies. He notes that PCOM’s support—from
research funding to departmental collaboration—has played an important role in advancing
this work.
He incorporates elements of this research into his instruction in virology and antiviral
pharmacology, helping PCOM School of Pharmacy students connect foundational science with current issues in therapeutic development.
The inclusion of faculty-led research in the PharmD curriculum reflects PCOM’s emphasis on evidence-based education and its commitment to preparing
students for diverse roles in clinical, academic, and research settings.